Preclinical Assets Market Anticipated To Witness Robust Growth, Surpassing $9.3 Billion By 2029

The Preclinical Assets Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].

What Is the Current Preclinical Assets Market Size and Its Estimated Growth Rate?
The market size for preclinical assets has been experiencing robust growth in the past few years, expanding from a worth of $5.87 billion in 2024 to an estimated $6.4 billion in 2025. This represents a compound annual growth rate (CAGR) of 9.1%. The growth observed in the precedent period can be linked to factors such as the need for drug development, progress in biotech, regulatory dictates, increased funding for research, and collaborative endeavors in scientific studies.

The market size for preclinical assets is predicted to enjoy robust growth in the coming years, with expectations to reach a value of $9.3 billion by 2029, boasting a compound annual growth rate (CAGR) of 9.8%. The predicted growth for this period can be accredited to factors such as the introduction of precision medicine and personalized treatments, the adoption of AI and machine learning, the growth of biobanking, emphasis on rare diseases, and government assistance and funding schemes. The period under forecast also highlights emerging trends such as advanced imaging techniques, 3D organoid models, multi-omics integration, improved predictive models, and the rise of automated and high-throughput screening technology.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12600

How Are Emerging Segments Shaping the Preclinical Assets Market Landscape?
The preclinical assets market covered in this report is segmented -

1) By Service: Bioanalysis And DMPK (Drug Metabolism And Pharmacokinetic) Studies, Toxicology Testing, Compound Management, Safety Pharmacology, Other Services
2) By Model Type: Patient Derived Organoid (PDO) Model, Patient Derived Xenograft Model
3) By End User: Biopharmaceutical Companies, Government Institutes, Other End-Users

Subsegments:
1) By Bioanalysis And DMPK (Drug Metabolism And Pharmacokinetic) Studies: Pharmacokinetics (PK) Studies, Pharmacodynamics (PD) Studies, Bioanalytical Method Development
2) By Toxicology Testing: Acute Toxicity Testing, Chronic Toxicity Testing, Genotoxicity Testing, Carcinogenicity Testing
3) By Compound Management: Compound Library Management, Sample Storage And Retrieval, High-Throughput Screening Support
4) By Safety Pharmacology: Cardiovascular Safety Assessments, Neurotoxicity Evaluations, Respiratory Safety Evaluations
5) By Other Services: Regulatory Support, Preclinical Study Design And Consulting, Custom Assay Development

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12600&type=smp

Which Growth Factors Are Influencing Preclinical Assets Market Expansion?
The expansion of the preclinical asset market is expected to be fueled by the rise in drug discovery. Drug discovery involves locating chemical substances that have potential medicinal uses and is the method by which new possible drugs are identified. Preclinical assets are critical in this process, providing necessary data and evidence to assist in choosing molecules for clinical development as potential candidates. For example, the European Federation of Pharmaceutical Industries and Associations (EFPIA), a Belgium-based organization that represents the pharmaceutical industry, reported in June 2023 that there was a significant increase in production in the European pharmaceutical industry. This increase shot from $352.48 billion in 2021 to $369.95 billion in 2022. As a result, the surge in drug discovery is pushing the expansion of the preclinical assets market.

Who Are the Dominant Players Across Different Preclinical Assets Market Segments?
Major companies operating in the preclinical assets market include Laboratory Corporation of America, IQVIA Inc., ICON PLC, Eurofins Scientific SE, PPD Inc., SGS SA, WuXi AppTec Co. Ltd., Intertrek Group PLC, Charles River Laboratories International Inc., Medpace Inc., Pharmaron Beijing Co. Ltd., Evotec SE, GenScript Biotech Corporation, Inotiv Inc., SRI International Inc., Shanghai Medicilon Inc., Biocytogen Pharmaceuticals Beijing Co. Ltd., AmplifyBio LLC, BioReliance Corporation, Pharmalegacy Laboratories Co. Ltd., Precigen Inc., ReproCELL Incorporated, InSphero AG, Crown Bioscience Inc., Comparative Biosciences Inc., TCG Lifesciences Pvt. Ltd., InVivo Biosystems, Pharmatest Services Ltd, Domainex Limited, Viroclinics Xplore

What Are the Latest Developing Trends in the Preclinical Assets Market?
Innovations in products are a rising trend in the preclinical assets sector. Leading companies in this market are concentrating on the creation of new products and solutions to consolidate their market dominance and attain a competitive edge. For illustration, in April 2022, Charles River Laboratories International, an American company that specializes in various preclinical and clinical laboratories, along with Valo Health Inc., a US technological company aimed at revolutionizing drug discovery, unveiled Logica, a drug solution powered by AI which converts clients' biological insights directly into optimized preclinical assets. Logica employs Charles River's preclinical expertise and Valo's AI-enabled Opal Computational Platform to deliver a revolutionized drug discovery to clients by combining targets into a singular integrated offering that smoothly leads to candidate nomination. Charles River's partnership with Valo allows it to merge its laboratory proficiency with molecular design technology, thereby ushering a new era in the industry by providing its clients with highly effective leads and candidates and connecting client costs to value generation.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/preclinical-assets-global-market-report

Which Geographic Regions Are Expected to Dominate the Preclinical Assets Market in the Coming Years?
North America was the largest region in the preclinical assets market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the preclinical assets market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Preclinical Assets Market?
2. What is the CAGR expected in the Preclinical Assets Market?
3. What Are the Key Innovations Transforming the Preclinical Assets Industry?
4. Which Region Is Leading the Preclinical Assets Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.